Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01365910 · ClinicalTrials.gov registry record · Phase 2
Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer
A Phase 2 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT01365910 is a Phase 2 study that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 30 participants.
The verdict
NCT01365910, a Phase 2 study, was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This phase II trial studies how well Linifanib works in treating patients with advanced, refractory colorectal cancer expressing k-Ras mutations. Linifanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG linifanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-06 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01365910
The ClinicalTrials.gov registry entry for NCT01365910 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which linifanib is the first listed.
NCT01365910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01365910 about?
NCT01365910 is a clinical study titled "Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer". This phase II trial studies how well Linifanib works in treating patients with advanced, refractory colorectal cancer expressing k-Ras mutations. Linifanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01365910?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2011-06. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01365910?
The interventions under investigation include: linifanib (DRUG).
Who is sponsoring clinical trial NCT01365910?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.